Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Creat membership Creat membership
Sign in

Forgot password?

Confirm
  • Forgot password?
    Sign Up
  • Confirm
    Sign In
Collection

toTop

If you have any feedback, Please follow the official account to submit feedback.

Turn on your phone and scan

home > search >

A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts

Author:
Endo, Mika  Miwa, Masanori  Ura, Masako  Tanimura, Hiromi  Taniguchi, Kenji  Miyazaki, Yoko  Ohwada, Jun  Tsukazaki, Masao  Niizuma, Satoshi  Murata, Takeshi  Ozawa, Sawako  Suda, Hitomi  Ogawa, Kotaro  Nanba, Eitaro  Nagao, Shunsuke  Shimma, Nobuo  Yamada-Okabe, Hisafumi  


Journal:
CANCER CHEMOTHERAPY AND PHARMACOLOGY


Issue Date:
2010


Abstract(summary):

Identification of a novel topoisomerase I inhibitor which shows superior efficacy and less individual variation than irinotecan hydrochloride (CPT-11). A novel camptothecin analog that is effective against breast cancer resistance protein (BCRP)-positive cells was screened, and a water soluble prodrug was generated. Antitumor activity of the prodrug was examined in BCRP-positive and -negative xenografts both as a single agent and in combination with other anti-cancer drugs. A novel camptothecin analog, CH0793076, was discovered. Because CH0793076 was found to be highly lipophilic, a water soluble prodrug (TP300) was generated. TP300 is stable in an acidic solution but is rapidly converted to CH0793076 under physiological pH conditions such as in sera. This efficient prodrug activation would minimize interpatient differences in pharmacokinetic and toxicity profiles. Unlike CPT-11, TP300 does not exhibit cholinergic interaction or cause acute diarrhea at effective doses. In mouse xenograft models, TP300 showed antitumor activity against both BCRP-positive and -negative xenografts, whereas CPT-11 was less active against BCRP-positive xenografts. In addition, the effective dose range (MTD/ED(50)) for TP300 was wider than for CPT-11 and TP300 showed additive or synergistic antitumor effects in combination with other anti-cancer drugs such as capecitabine, oxaliplatin, cisplatin, bevacizumab and cetuximab. It is therefore expected that TP300 will provide an additional treatment option for patients who will undergo chemotherapy with camptothecins.


Page:
363---371


Similar Literature

Submit Feedback

This function is a member function, members do not limit the number of downloads